{"nctId":"NCT00561080","briefTitle":"Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)","startDateStruct":{"date":"2007-10-26","type":"ACTUAL"},"conditions":["Prevention of : Herpes-Zoster"],"count":759,"armGroups":[{"label":"Single Dose of Zostavax","type":"EXPERIMENTAL","interventionNames":["Biological: Zostavax"]},{"label":"Zostavax - Day 0 and Month 1","type":"EXPERIMENTAL","interventionNames":["Biological: Zostavax"]},{"label":"Zostavax - Day 0 and Month 3","type":"EXPERIMENTAL","interventionNames":["Biological: Zostavax"]}],"interventions":[{"name":"Zostavax","otherNames":["Zoster vaccine live"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥ 70 years\n2. Varicella history-positive or residence for \\> 30 years in a country with endemic VZV infection\n3. Signed informed consent form prior to any study procedure\n\nExclusion Criteria:\n\n1. Febrile illness within the last 72 hours before the first vaccination\n2. Prior herpes-zoster episode clinically diagnosed by a physician\n3. Prior receipt of varicella or zoster vaccine\n4. Exposure to varicella or herpes-zoster within the 4 weeks prior to the first vaccination\n5. Significant underlying illness preventing completion of the study vaccination schedules,\n6. Known active tuberculosis,\n7. Immune deficiency disorder, including active neoplastic disease within the prior 5 years,\n8. Immune function impairment caused by medical condition or immunosuppressive therapy, or any other cause,\n9. Receipt of any inactivated vaccine within the 2 weeks prior to the first vaccination,\n10. Receipt of any other live vaccine within the 4 weeks prior to the first vaccination,\n11. Receipt of immunoglobulins or blood-derived products within the 5 months prior to the first vaccination,\n12. Concomitant use of non-topical antiviral therapy","healthyVolunteers":true,"sex":"ALL","minimumAge":"70 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks After Each Vaccination: Groups 2 and 3","description":"Blood samples taken at 4 weeks post each vaccination to determine the geometric mean titer (GMT) of VZV antibodies via Glycoprotein Enzyme Linked Immunosorbent Assay (gpELISA).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"498.8","spread":null},{"groupId":"OG001","value":"523.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"555.3","spread":null},{"groupId":"OG001","value":"410.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of VZV Antibodies 4 Weeks After Vaccination: Group 1","description":"Blood sample taken at 4 weeks post vaccination to determine the geometric mean titer (GMT) of VZV antibodies via gpELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"233.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"550.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-vaccination to 4 Weeks Post-dose 1 in Groups 1, 2 and 3 and 4 Weeks Post-dose 2 in Groups 2 and 3","description":"Blood sample taken at predose (Day 0) and 4 weeks post each vaccination to determine the geometric mean titer (GMT) of VZV antibodies via gpELISA. The GMFR was calculated following each vaccination as GMT Post-dose/GMT Pre-vaccination","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.35","spread":null},{"groupId":"OG001","value":"2.37","spread":null},{"groupId":"OG002","value":"2.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"2.64","spread":null},{"groupId":"OG002","value":"1.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titre of VZV Antibodies 12 Months Post-last Dose","description":"Blood sample taken at 1 year post last vaccination to determine the geometric mean titer (GMT) of varicella antibodies via gpELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"246.8","spread":null},{"groupId":"OG001","value":"261.1","spread":null},{"groupId":"OG002","value":"266.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-Vaccination To 12 Months Post-dose 1 in Group 1 And From Pre-Vaccination To 12 Months Post-dose 2 in Groups 2 and 3","description":"Blood sample taken at predose and 1 year post last vaccination to determine the GMFR of varicella antibodies via gpELISA. Geometric mean fold rise was calculated for each arm as GMT 12-month post last dose divided by pre-vaccination GMT.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":null},{"groupId":"OG001","value":"1.16","spread":null},{"groupId":"OG002","value":"1.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titre (GMT) of VZV Antibodies 24 and 36 Months Post-dose 1 in Group 1 and the 24 and 36 Months Post-dose 2 in Groups 2 and 3","description":"Blood sample taken at 36 months post last-vaccination to determine the geometric mean titer (GMT) of varicella antibodies via gpELISA.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-Vaccination To 24 And 36 Months Post-dose 1 in Group 1 and From Pre-vaccination To 24 And 36 Months Post-dose 2 in Groups 2 and 3","description":"Blood samples were to be taken at predose and 24 months post- last vaccination in Groups 1 , 2, and 3 to determine the GMFR of varicella antibodies via gpELISA. Geometric mean fold rise was to be calculated for each arm as GMT 24-month post last dose divided by pre-vaccination GMT.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported a Solicited Injection Site Reaction : Post-dose 1","description":"Participants entered data into daily dairy card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null},{"groupId":"OG001","value":"46.0","spread":null},{"groupId":"OG002","value":"42.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported a Solicited Injection Site Reaction: Post-dose 2","description":"Participants entered data into daily dairy card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"42.2","spread":null},{"groupId":"OG002","value":"42.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 1","description":"The percentage of participants who reported an injection site reaction that was not specifically prompted by the diary card within 28 day of 1st vaccination was recorded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"4.8","spread":null},{"groupId":"OG002","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 2","description":"The percentage of participants that reported an injection site reaction that was not specifically prompted by the diary card within 28 days post-dose 2 was recorded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"3.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-dose 1","description":"Percentage of participants who reported herpes zoster or zoster-like rash following the 1st dose of vaccine were recorded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-Dose 2","description":"Percentage of participants who reported herpes zoster or zoster-like rash following the 2nd dose of vaccine were recorded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 1","description":"Percentage of participants that reported varicella or varicella-like rash following the 1st dose of vaccine were recorded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 2","description":"Percentage of participants that reported varicella or varicella-like rash following the 2nd dose of vaccine were recorded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0.4","spread":null},{"groupId":"OG002","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported a Systemic Adverse Event: Post-dose 1","description":"An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":null},{"groupId":"OG001","value":"32.7","spread":null},{"groupId":"OG002","value":"25.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported a Systemic Adverse Event: Post-dose 2","description":"An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized,","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"20.7","spread":null},{"groupId":"OG002","value":"15.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 1","description":"An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) and were reported as at least possibly related to the vaccine were summarized","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"4.0","spread":null},{"groupId":"OG002","value":"8.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 2","description":"An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) and were reported as at least possibly related to the vaccine were summarized,","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"3.4","spread":null},{"groupId":"OG002","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported a Serious Adverse Event: Post-dose 1","description":"A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \"other important medical event\" based on medical judgement. The percentage of participants who reported an SAE within 28 days of 1st dose of vaccine were recorded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"2.8","spread":null},{"groupId":"OG002","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported a Serious Adverse Event: Post-dose 2","description":"A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \"other important medical event\" based on medical judgement. The percentage of participants who reported an SAE within 28 days of 1st dose of vaccine were recorded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Reported a Vaccine-related Serious Adverse Event","description":"A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \"other important medical event\" based on medical judgement. The percentage of participants who reported an SAE during the entire study period that was considered at least possibly -related to the vaccine were recorded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Died During the Study","description":"The number of participants who died for any reason during the study was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"1.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":253},"commonTop":["Injection site erythema","Injection site swelling","Injection site pain","Headache"]}}}